Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | ||
Nplate | Romiplostim | Chronic immune (idiopathic) thrombocytopenic purpura (ITP) | Do not list | Complete | ||
Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete | ||
Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | ||
Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete |